Dr. Brian Weiss, MD
Claim this profileCincinnati Children's Hospital Medical Center
Expert in Neuroblastoma
Studies Tumors
27 reported clinical trials
48 drugs studied
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
2Tumors
Stage IV
SMARCB1 positive
SMARCA4 positive
Affiliated Hospitals
Clinical Trials Brian Weiss, MD is currently running
Imetelstat + Chemotherapy
for Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.
Recruiting1 award Phase 14 criteria
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Brian Weiss, MD
Clinical Trial Related2 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Brian Weiss, MD has experience with
- Dinutuximab
- Vorinostat
- 131I-MIBG
- Temozolomide
- Lorlatinib
- Irinotecan
Breakdown of trials Brian Weiss, MD has run
Neuroblastoma
Tumors
Neurofibromatosis
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian Weiss, MD specialize in?
Brian Weiss, MD focuses on Neuroblastoma and Tumors. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Brian Weiss, MD currently recruiting for clinical trials?
Yes, Brian Weiss, MD is currently recruiting for 8 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Brian Weiss, MD has studied deeply?
Yes, Brian Weiss, MD has studied treatments such as Dinutuximab, Vorinostat, 131I-MIBG.
What is the best way to schedule an appointment with Brian Weiss, MD?
Apply for one of the trials that Brian Weiss, MD is conducting.
What is the office address of Brian Weiss, MD?
The office of Brian Weiss, MD is located at: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039 United States. This is the address for their practice at the Cincinnati Children's Hospital Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.